Mineral salt-sulfonic acid compositions and methods of use

Abstract

The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.

We claim the following: 
     
         1 . Method of treating mucosal disorders with a composition comprising zinc gluconate, taurine and polyvinylpyrrolidone (PVP), said method comprising:
 applying to each dermal area in need thereof a pharmaceutically effective amount of said composition.   
     
     
         2 . The method according to  claim 1 , wherein said composition comprises between 0.25% w/w to 5.5% w/w zinc gluconate, between 0.25% w/w to 30% w/w taurine and from 0.04% w/w to 15% w/w PVP. 
     
     
         3 . The method according to  claim 2 , wherein said composition comprises from between 0.20% w/w to 5.5% w/w zinc gluconate. 
     
     
         4 . The method according to  claim 2 , wherein said composition comprises from between 0.5% w/w to 8.0% w/w taurine. 
     
     
         5 . The method according to  claim 2 , wherein said composition comprises from between 0.5% w/w/ to 4.0% w/w taurine. 
     
     
         6 . The method according to  claim 1 , wherein said composition comprises 0.5% w/w zinc gluconate, 1.0% w/w taurine and 4.0% w/w PVP. 
     
     
         7 . The method according to  claim 1 , wherein said composition comprises comprises 0.5% w/w zinc gluconate, 1.0% w/w taurine and 8.0% w/w PVP. 
     
     
         8 . The method according to  claim 1 , wherein said composition comprises comprises 2.0% w/w zinc gluconate, 4.0% w/w taurine and 4.0% w/w PVP. 
     
     
         9 . The method according to  claim 1 , wherein said composition is in the form of a liquid, a solid, a gel, a paste, an emulsion, an ointment, a foam or a spray. 
     
     
         10 . The method according to  claim 1 , wherein said composition is delivered by a vehicle selected from the group consisting of a sponge, gel cap, suppository and a lozenge. 
     
     
         11 . The method according to  claim 1 , wherein said composition has a pH between 3.5 and 4.5. 
     
     
         12 . The method according to  claim 1 , wherein said composition has a pH between 5.5 and 7.5. 
     
     
         13 . The method according to  claim 1 , wherein said mucosal disorder comprises mucositis. 
     
     
         14 . The method according to  claim 1 , wherein said mucosal disorder is selected from oral stomatitis, oral mucositis, an oral ulceration. 
     
     
         15 . The method according to  claim 1 , wherein said composition is administered one or more times per day, once every day, once every other day, once weekly or once a month. 
     
     
         16 . The method according to  claim 1 , wherein said composition is administered topically, orally or topically and orally.